Literature DB >> 34233380

Pathologically stiff erythrocytes impede contraction of blood clots.

Valerie Tutwiler1, Rustem I Litvinov1,2, Anna Protopopova1, Chandrasekaran Nagaswami1, Carlos Villa3, Eric Woods4, Osheiza Abdulmalik5, Don L Siegel3, J Eric Russell6, Vladimir R Muzykantov7, Wilbur A Lam8, David R Myers8, John W Weisel1.   

Abstract

BACKGROUND: Blood clot contraction, volume shrinkage of the clot, is driven by platelet contraction and accompanied by compaction of the erythrocytes and their gradual shape change from biconcave to polyhedral, with the resulting cells named polyhedrocytes.
OBJECTIVES: Here, we examined the role of erythrocyte rigidity on clot contraction and erythrocyte shape transformation.
METHODS: We used an optical tracking methodology that allowed us to quantify changes in contracting clot size over time. RESULTS AND
CONCLUSIONS: Erythrocyte rigidity has been shown to be increased in sickle cell disease (SCD), and in our experiments erythrocytes from SCD patients were 4-fold stiffer than those from healthy subjects. On average, the final extent of clot contraction was reduced by 53% in the clots from the blood of patients with SCD compared to healthy individuals, and there was significantly less polyhedrocyte formation. To test if this reduction in clot contraction was due to the increase in erythrocyte rigidity, we used stiffening of erythrocytes via chemical cross-linking (glutaraldehyde), rigidifying Wrightb antibodies (Wrb ), and naturally more rigid llama ovalocytes. Results revealed that stiffening erythrocytes result in impaired clot contraction and fewer polyhedrocytes. These results demonstrate the role of erythrocyte rigidity in the contraction of blood clots and suggest that the impaired clot contraction/shrinkage in SCD is due to the reduced erythrocyte deformability, which may be an underappreciated mechanism that aggravates obstructiveness of erythrocyte-rich (micro)thrombi in SCD.
© 2021 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  blood clotting; clot retractions; coagulation; sickle cell disease; thrombosis

Mesh:

Year:  2021        PMID: 34233380     DOI: 10.1111/jth.15407

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  To deform or not to deform: the evolutionary basis of mammalian red blood cell deformability.

Authors:  Valerie Tutwiler
Journal:  Biophys J       Date:  2021-08-03       Impact factor: 3.699

Review 2.  Physical Properties of Blood and their Relationship to Clinical Conditions.

Authors:  Tamas Alexy; Jon Detterich; Philippe Connes; Kalman Toth; Elie Nader; Peter Kenyeres; Jose Arriola-Montenegro; Pinar Ulker; Michael J Simmonds
Journal:  Front Physiol       Date:  2022-07-06       Impact factor: 4.755

3.  ADP and Thromboxane Inhibitors Both Reduce Global Contraction of Clot Length, While Thromboxane Inhibition Attenuates Internal Aggregate Contraction.

Authors:  Kevin T Trigani; Michael E DeCortin; Scott L Diamond
Journal:  TH Open       Date:  2022-06-13

4.  Effects of diabetes mellitus complicated by admission hyperglycemia on clot histological composition and ultrastructure in patients with acute ischemic stroke.

Authors:  Jun Lu; Juan Chen; Daming Wang; Qun Gao; Peng Qi; Junjie Wang; Shen Hu; Ximeng Yang; Jingwen Fan; Ling Li; Yao Lu
Journal:  BMC Neurol       Date:  2022-04-05       Impact factor: 2.474

5.  Extent of intravital contraction of arterial and venous thrombi and pulmonary emboli.

Authors:  Rafael R Khismatullin; Shahnoza Abdullayeva; Alina D Peshkova; Khetam Sounbuli; Natalia G Evtugina; Rustem I Litvinov; John W Weisel
Journal:  Blood Adv       Date:  2022-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.